FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

wasiiiigtori,	D.C.	20049	

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					Oi	Secui	011 30(11) 0	טו ווופ	Investment	Compa	ally Act	01 1940						
Name and Address of Reporting Person*     Horning Sandra				2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [OLMA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
110111111	g <u>Banura</u>										_	-		X Directo	or		10% Ow	ner
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/17/2022								$\dashv$	Officer below)	(give title		Other (spelow)	pecify
C/O OLE	EMA PHAF	RMACEUTICAI	LS, INC.			11112	022											
512 2ND	STREET,	4TH FLOOR																
(Street)						f Ame /17/2		Date o	of Original Fi	iled (M	/lonth/Da		Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
SAN FRANCISCO CA 94107														filed by More than One Repo		•	- 1	
(City)	(S	tate)	(Zip)															
		Tab	le I - Non	-Deriva	ative	e Se	curities	s Ac	quired, D	Dispo	osed o	f, or Be	neficial	ly Owned	ı			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D						ear)	2A. Deemed Execution Date, if any (Month/Day/Yea		e, Transaction Dispos Code (Instr. 5)		Disposed	urities Acquired (A) sed Of (D) (Instr. 3, 4		Benefici Owned F	ally Following	Form: Direct (D) or Indirect (I) (Instr. 4)	ect c irect E	7. Nature of Indirect Beneficial Ownership
								Code	V Amount (A) or (D)		Price		ansaction(s) str. 3 and 4)			(Instr. 4)		
		٦	Γable II - Ε						uired, Dis					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Day if any (Month/Day/	ate, Ti	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Own For Dire or I (I) (	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					ode	v	(A)	(D)	Date Exercisable		oiration te	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$3.61 <sup>(1)</sup>	06/17/2022 <sup>(1)</sup>			A		21,520		(2)	06/1	16/2032	Common Stock	21,520	\$0	21,520		D	

## **Explanation of Responses:**

- 1. This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "\$3.61" as shown
- 2. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service

/s/ John B. Moriarty, Jr., Attorney-in-Fact

06/27/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.